Drugs targeting the PD-1/PD-L1 and CTLA-4/CD80/CD86 axes alone or in combination have been reported to be safe and effective among patients with advanced HCC (Figure 3). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.